CytoDyn (CYDY) Work In Process (2021 - 2022)

CytoDyn (CYDY) posted Work In Process of $63.2 million for Q1 2022, down 4.35% on a QoQ basis from $66.0 million in Q4 2021.

CytoDyn (CYDY) Work In Process (2021 - 2022) Analysis & Trends

CytoDyn's Work In Process history runs 2 years deep, the most recent figure standing at $63.2 million for Q1 2022.

Quarterly Work In Process changed N/A year-over-year to $63.2 million in Q1 2022, while the trailing twelve-month figure through Feb 2022 was $63.2 million (changed N/A YoY) and the FY2021 annual result came in at $65.4 million, changed N/A from the prior year.
Work In Process was $63.2 million for Q1 2022 at CytoDyn, down from $66.0 million in the prior quarter.
Across five years, Work In Process topped out at $66.0 million in Q4 2021 and bottomed at $63.2 million in Q1 2022.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn
4	NuCana	279.75 Bn	279.75 Bn	-
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-
10	CytoDyn	267.79 Mn	267.79 Mn	-

Download Data